Nav: Home

New gene therapy for pseudarthrosis trialed at Kazan University

December 02, 2016

A team headed by Professor Albert Rizvanov, director of the Gene and Cell Technologies Open Lab, created a gene therapy drug that encodes growth factors for the stimulation of blood vessel and bone formation. The combination was highly effective in a patient admitted to the Republican Clinical Hospital in Kazan, Russia. The treatment was approved by the ethical committee, supported by the Ministry of Healthcare of Tatarstan and published in BioNanoScience.

Professor Rizvanov explains: «We combined a demineralized bone transplant with recombinant genetic material, which carries genes for vascular endothelial growth factor, to stimulate new blood vessel growth (angiogenesis), and bone morphogenetic protein to stimulate bone growth (osteogenesis). Thus survival of transplant and bone tissue formation was achieved at the desired location. We were able to translate our basic and pre-clinical research and are the first to document the efficacy of such therapy in a real clinical case of pseudarthrosis».

As the team leader noted, for a long time clinicians have tried standard methods of bone regeneration - osteosynthesis and osteoplasty - when an absent bone part is replaced with allogenic, cadaveric or demineralized bone matrix. In the latter case cells and minerals are removed from an animal bone tissue, and only the matrix is left - a "bone-like sponge" that can be used to fill in defects in the bone to stimulate formation of a new bone. However, current procedures often result in complications, such as resorption of the transplant. Parts of the problem are poor blood supply and low levels of pro-osteogenic growth factors.

Our therapy, a combination of demineralized bone with gene therapy, is a promising solution for the currently existing complication problems in pseudarthrosis and other bone defects and fracture treatments. We now plan to offer such innovative treatments at the Kazan University Clinic as a part of a new clinical trial program at strategic academic unit Translational 7P Medicine for biomedical and translational research.

-end-



Kazan Federal University
Mysterious gene transcripts after cancer therapy
Drugs that are used in cancer therapy to erase epigenetic alterations in cancer cells simultaneously promote the production of countless mysterious gene transcripts, scientists from the German Cancer Research Center now report in Nature Genetics.
Gene therapy could 'turn off' severe allergies
A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology research at The University of Queensland.
Lipid nanoparticles for gene therapy
Twenty-five years have passed since the publication of the first work on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as a system for delivering drugs.
New gene therapy for pseudarthrosis trialed at Kazan University
A team headed by Professor Albert Rizvanov, director of the Gene and Cell Technologies Open Lab, created a gene therapy drug that encodes growth factors for the stimulation of blood vessel and bone formation.
WSU researcher develops safer gene therapy
A Washington State University researcher has developed a way to reduce the development of cancer cells that are an infrequent but dangerous byproduct of gene therapy.
New gene therapy prevents muscle wasting associated with cancer
A new gene therapy could be used to prevent the loss of muscle mass and physical strength associated with advanced cancer
On the path to controlled gene therapy
The ability to switch disease-causing genes on and off remains a dream for many physicians, research scientists and patients.
Gene therapy against brain cancer
A team from the International School for Advanced Studies (SISSA) in Trieste has obtained very promising results by applying gene therapy to glioblastoma.
First gene therapy successful against human aging
Elizabeth Parrish, CEO of Bioviva USA Inc. has become the first human being to be successfully rejuvenated by gene therapy, after her own company's experimental therapies reversed 20 years of normal telomere shortening.
Designing gene therapy
Scientists in the Barabas group at EMBL have increased the efficiency of a genome-engineering tool called Sleeping Beauty, which is showing promise in clinical trials for leukemia and lymphoma immunotherapies.

Best Science Podcasts 2017

We have hand picked the best science podcasts for 2017. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.

Now Playing: Radiolab

Truth Trolls
Today, a third story of folks relentlessly searching for the truth. But this time, the truth seekers are an unlikely bunch... internet trolls.


Now Playing: TED Radio Hour

Rethinking School
For most of modern history, humans have placed smaller humans in institutions called schools. But what parts of this model still work? And what must change? This hour, TED speakers rethink education.TED speakers include teacher Tyler DeWitt, social entrepreneur Sal Khan, international education expert Andreas Schleicher, and educator Linda Cliatt-Wayman.